Bruton tyrosine kinase, or BTK, sits at a critical junction in the B-cell receptor signaling pathway, and blocking it cripples the survival machinery of malignant lymphocytes. The first-generation inhibitor ibrutinib proved the concept, improving progression-free survival in relapsed or refractory disease, but its off-target activity produced troublesome cardiac events, bleeding, and other toxicities. Second-generation inhibitors zanubrutinib and acalabrutinib were engineered for greater selectivity, and clinical momentum has been rapid: acalabrutinib combined with bendamustine and rituximab recently earned preferred first-line status in the NCCN 2025 guideline after the ECHO trial demonstrated a complete response rate of 88.9 percent and a median progression-free survival of 28.6 months, while zanubrutinib gained a first-line indication restricted to TP53-mutant disease after Phase II trials recorded complete response rates of 88 percent in that high-risk cohort. Yet guidelines remained fragmented, because trial designs varied so widely that head-to-head conclusions were impossible without pooling the evidence.

To close that gap, investigators systematically searched PubMed, Cochrane, and Embase for studies published before January 31, 2025, identifying thousands of records: 715 studies touching acalabrutinib, 3,398 on ibrutinib, and 486 on zanubrutinib. After duplicate removal and rigorous screening by independent reviewers, 70 studies survived, comprising four randomized controlled trials, three retrospective-prospective observational studies, and 63 single-arm cohort studies. Together they encompassed 1,641 treatment-naïve patients and 1,791 patients with relapsed or refractory disease, with median ages ranging from 56 to 75 years in the newly diagnosed group and 61 to 74 years in the relapsed group. The analysis was registered with PROSPERO, conducted under PRISMA reporting standards, and quality was assessed with the Cochrane Risk of Bias 2 tool for randomized trials and the MINORS instrument for single-arm studies. Statistical pooling used random-effect models where heterogeneity exceeded an I-squared value of 50 percent, with sensitivity analyses and funnel plots, Egger’s test, and Begg’s test confirming the absence of publication bias.

The headline results are striking. In treatment-naïve patients, BTK inhibitor-based therapy achieved a pooled complete response rate of 76.5 percent and an objective response rate of 94.5 percent. In relapsed or refractory patients, the corresponding figures fell to 43.2 percent and 81.2 percent, illustrating how much harder the disease is to subdue once it has already weathered prior treatment. Subgroup analysis by drug type then revealed a clear hierarchy in the newly diagnosed setting: zanubrutinib delivered a complete response rate of 95.2 percent, acalabrutinib 89.3 percent, and ibrutinib only 61.3 percent, a statistically significant difference with a p-value of 0.0042. Objective response rates followed the same pattern, at 99.1 percent for zanubrutinib, 97.7 percent for acalabrutinib, and 90.0 percent for ibrutinib. In the relapsed setting, however, the three drugs performed comparably, with no significant differences in either complete response or objective response rates.

Safety data from 53 studies added crucial nuance. Hematologic toxicities dominated, with pooled rates of neutropenia around 28 to 34 percent, thrombocytopenia around 33 to 35 percent, and anemia between 16 and 20 percent across patient groups. Zanubrutinib-based therapy showed significantly lower rates of neutropenia in treatment-naïve patients and lower thrombocytopenia in relapsed patients than its two rivals. Infection emerged as the most common non-hematologic adverse event, affecting roughly a third of newly diagnosed patients and nearly 40 percent of relapsed patients, and zanubrutinib carried a notably higher infection rate of 66.1 percent in the relapsed setting. Ibrutinib, by contrast, was associated with a significantly elevated rate of cardiac events at 7.7 percent, compared with just 2.0 percent for acalabrutinib and 0.2 percent for zanubrutinib, while acalabrutinib showed the lowest hemorrhage rate at 9.3 percent. These safety profiles, combined with superior efficacy, argue strongly for the newer agents in frontline care.

The analysis also dissected how best to combine BTK inhibitors with other therapies, a question that has generated considerable confusion in the clinic. In newly diagnosed patients, triple regimens pairing a BTK inhibitor with an anti-CD20 monoclonal antibody and small-molecule agents such as venetoclax, lenalidomide, or proteasome inhibitors achieved a complete response rate of 88.0 percent and an objective response rate of 97.1 percent, numerically outperforming regimens built on traditional chemotherapy with or without stem cell transplantation, though the difference did not reach statistical significance. In relapsed disease, the most impressive complete response rates came from combining BTK inhibitors with CAR T-cell immunotherapy at 80.0 percent, and with anti-CD20 antibodies plus small-molecule therapy at 68.3 percent, both significantly better than monotherapy. Because only 20 patients in the entire dataset received the BTK inhibitor plus CAR-T combination, the authors urge caution in interpreting that result, but the signal is compelling.

The findings carry substantial biological and clinical logic. BTK inhibitor monotherapy rarely achieves deep, durable remissions, and acquired resistance eventually defeats many patients, particularly in the relapsed setting. Pairing BTK blockade with agents attacking complementary pathways, such as the BCL2 inhibitor venetoclax or immunomodulators like lenalidomide, addresses that vulnerability. An observational cohort study cited in the analysis showed that BTK inhibitor-venetoclax regimens could overcome the unfavorable prognosis of TP53-mutated disease, and the ENRICH trial demonstrated that ibrutinib plus rituximab outperformed standard immunochemotherapy with fewer grade 3 or higher adverse events in untreated patients. The meta-analysis now provides quantitative support for chemotherapy-free strategies, showing that small-molecule combinations can match or exceed chemotherapy-based regimens without their cumulative toxicity, a potentially transformative option for elderly and frail patients who cannot tolerate intensive chemoimmunotherapy.

The authors are candid about limitations. Most included studies were single-arm trials vulnerable to selection bias; heterogeneity was moderate to high, reflecting differences in patient demographics, TP53 status, treatment line, and follow-up duration; and most studies did not report progression-free or overall survival in analyzable form, precluding pooled survival analysis and leaving long-term benefit unproven. Nonetheless, the central conclusions stand on robust methodology: acalabrutinib and zanubrutinib are more promising than ibrutinib as first-line options, owing to superior response rates and more favorable safety profiles, and chemotherapy-free combination regimens can partially overcome the traditionally grim prognosis of relapsed disease. As BTK inhibitors continue to infiltrate frontline protocols, this synthesis offers clinicians a data-driven roadmap for sequencing therapy, and it sets a clear agenda for the randomized head-to-head trials that the field still sorely needs.

Subject of Research: Comparative efficacy and safety of Bruton tyrosine kinase inhibitors in treatment-naïve and relapsed/refractory mantle cell lymphoma

Article Title: Comparative Efficacy of BTK Inhibitors in Treatment‐Naïve and Relapsed/Refractory Mantle Cell Lymphoma: A Systematic Review and Meta‐Analysis

Article References: Xu, F., Zou, X., Yang, Y., Zhou, K., & Huang, W. (2026). Comparative Efficacy of BTK Inhibitors in Treatment‐Naïve and Relapsed/Refractory Mantle Cell Lymphoma: A Systematic Review and Meta‐Analysis. Journal of Cellular and Molecular Medicine, 30(17), Article e71340. https://doi.org/10.1111/jcmm.71340

Image Credits: AI Generated

DOI: 10.1111/jcmm.71340

Keywords: mantle cell lymphoma, BTK inhibitors, acalabrutinib, zanubrutinib, ibrutinib, meta-analysis, clinical trials, hematology, chemotherapy-free regimens, lymphoma treatment, venetoclax, CAR-T therapy

The new analysis, published in Annals of Hematology by a team led by researchers at the Children’s Hospital of Chongqing Medical University, pooled data from 83 studies covering 542 patients treated with ruxolitinib-based regimens. Because no randomized controlled trials have ever evaluated ruxolitinib in hemophagocytic lymphohistiocytosis, the investigators conducted a systematic review and single-arm meta-analysis, registered prospectively with PROSPERO under identifier CRD42025639580. Their headline finding: the pooled overall response rate was 87.2 percent, with a 95 percent confidence interval of 80.8 to 92.7 percent and moderate statistical heterogeneity. When the authors split the results by disease subtype, a clear divide emerged. Patients with primary, or familial, hemophagocytic lymphohistiocytosis—a genetic disorder of immune regulation—achieved a response rate of 100 percent in the pooled data, compared with 82.4 percent in secondary forms triggered by infections, malignancies, or autoimmune disease, a difference that was statistically significant.

Survival figures told a similar story in the short term. The pooled overall survival rate was 91.6 percent at two months, falling to 81.6 percent at six months and 73.9 percent at one year, reflecting the relentless attrition that characterizes this syndrome even under modern therapy. Again, the primary form showed an advantage: 100 percent survival at two months versus 87.7 percent in secondary disease. The authors emphasize that these estimates remained robust in sensitivity analyses that excluded individual case reports, which are often criticized for publication bias since clinicians tend to publish successes rather than failures. Of the 83 included studies, 27 were single-arm trials or cohort studies while 56 were case reports or series, making the exclusion analysis a critical test of whether the headline numbers were propped up by anecdote. They were not.

To understand why these results matter, it helps to understand what ruxolitinib actually does. The drug is an inhibitor of Janus kinases 1 and 2, enzymes that sit at the receiving end of signaling pathways used by many inflammatory cytokines, including interferon-gamma and interleukins that drive T-cell and macrophage activation. In hemophagocytic lymphohistiocytosis, hyperactivated CD8-positive T cells and macrophages flood the body with these cytokines, causing fever, spleen enlargement, falling blood counts, liver injury, and, in the worst cases, multi-organ failure. By dampening cytokine signaling at the intracellular level, ruxolitinib acts upstream of the cellular destruction, calming the storm rather than simply suppressing the immune system wholesale with cytotoxic chemotherapy. This mechanism is why hematologists began experimenting with it off-label in the most desperate cases—patients failing standard etoposide-based regimens, for instance, or infants with genetic disease awaiting stem cell transplantation.

The distinction between primary and secondary disease is central to the new findings. Primary hemophagocytic lymphohistiocytosis arises from inherited defects in genes governing the cytotoxic machinery of natural killer cells and CD8 T cells, such as perforin pathways, and historically it was almost always fatal in infancy without hematopoietic stem cell transplantation. Secondary, or acquired, forms erupt on top of infections like Epstein-Barr virus, malignancies, or autoimmune conditions, and their biology is more heterogeneous, reflecting diverse underlying triggers. The higher pooled response rate in the primary form may seem counterintuitive at first—genetic disease might be expected to be harder to treat—but it fits with the drug’s mechanism. In primary disease, the cytokine loop is driven by a relatively uniform defect in cytotoxic function, and blocking the downstream signaling amplifiers may interrupt the feedback circuit very effectively. Secondary disease, by contrast, is entangled with the underlying trigger: a lymphoma continues to grow, a viral infection persists, and ruxolitinib alone cannot remove the source of the inflammation. The authors also observed more frequent pancreatic injury and severe hematological toxicity in the primary group, hinting that treatment intensity or disease biology differs between the subtypes in ways that deserve dedicated study.

Safety data from the synthesis add important nuance for clinicians weighing the drug at the bedside. The most frequent adverse events across the pooled population were infections at 9.3 percent, neutropenia at 7.5 percent, and hepatic dysfunction at 7.0 percent. These figures are notable because they are modest for a drug used in critically ill, profoundly immunosuppressed patients, but they are not trivial. Ruxolitinib’s immunosuppressive mechanism raises a theoretical concern about reactivation of latent infections, and cytomegalovirus reactivation in particular has been reported in clinical experience with the drug. The analysis does not settle that question definitively, and the authors are candid that rare disease research carries inherent limitations: no randomized comparisons, heterogeneous dosing and combination regimens, variable definitions of response across studies, and follow-up that is often short in a syndrome where patients may die quickly or be rescued by transplantation.

Those caveats frame the study’s real contribution. By aggregating every available strand of evidence—trials, cohorts, and hundreds of individually reported cases—the analysis provides the first quantitative benchmark for what clinicians can realistically expect from ruxolitinib-based therapy in each subtype. An 87 percent pooled response rate across the spectrum, with survival above 90 percent at two months, is a signal strong enough to inform practice today and to shape the design of the trials that must follow. The subgroup difference is arguably the most actionable finding: it suggests that in secondary hemophagocytic lymphohistiocytosis, ruxolitinib should probably be positioned as part of a strategy that simultaneously attacks the underlying trigger, whether that is antiviral therapy, chemotherapy for lymphoma, or immunosuppression for autoimmune disease, rather than as monotherapy expected to carry the patient alone.

The authors, led by Zirui Ding with senior authorship from Xi Yang, Xiaodong Zhao, and Ximing Xu among a team spanning Chongqing and Tokyo, including Hirokazu Kanegane of Institute of Science Tokyo, write that their findings provide critical guidance for clinical practice and future trial design despite the limitations inherent in studying a rare disease. The research was supported by grants from Chongqing municipal health and science funding programs, and the work reflects the growing capacity of pediatric immunology and hematology centers in China to mount large evidence syntheses in ultra-rare conditions where no single institution sees enough patients to study them alone.

For the rare disease community, the study lands at a moment of genuine momentum. Ruxolitinib has already been tested in randomized trials for graft-versus-host disease and is approved for several myeloproliferative neoplasms, giving physicians extensive familiarity with its dosing and toxicity profile. The new meta-analysis extends that familiarity into one of hematology’s most lethal emergencies, and its subtype-specific numbers give trial designers a clear benchmark against which future randomized studies of ruxolitinib in primary and secondary disease can be powered. What remains to be shown is whether the dramatic early responses translate into durable cures, particularly for patients with genetic disease who ultimately need stem cell transplantation, and whether the drug’s benefit in secondary forms depends critically on how aggressively the underlying trigger is treated alongside it. Those answers will require the very trials this synthesis is designed to enable.

Subject of Research: Efficacy and safety of the JAK1/JAK2 inhibitor ruxolitinib in primary versus secondary hemophagocytic lymphohistiocytosis

Article Title: Differential efficacy and safety of ruxolitinib in primary versus secondary hemophagocytic lymphohistiocytosis: a systematic review and meta-analysis

Article References: Ding, Z., Zhang, Z., Dou, Y., Jia, Y., An, Y., Tang, X., Kanegane, H., Xu, X., Zhao, X., & Yang, X. (2026). Differential efficacy and safety of ruxolitinib in primary versus secondary hemophagocytic lymphohistiocytosis: a systematic review and meta-analysis. Annals of Hematology. https://doi.org/10.1007/s00277-026-07274-9

Image Credits: AI Generated

DOI: 10.1007/s00277-026-07274-9

Keywords: hemophagocytic lymphohistiocytosis, ruxolitinib, JAK1/JAK2 inhibitor, meta-analysis, primary HLH, secondary HLH, overall response rate, overall survival, adverse events, rare disease, immunotherapy, hematology